Latest Articles

With the increasing complexities of current IND programs, it is critical to work with regulatory agencies to seek input early in the process. read more

Sponsors sometimes optimize too narrowly for the next milestone instead of the full development path. A formulation may be sufficient for an early study but still be poorly positioned for robust scale-up, transfer, or validation. That’s where delays and added costs show up. read more